Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7350854 | 0.85 | POLB (0.68) | ALDH1A1HTTLMNAHPGDMAPK1 | |
| SCHEMBL7227451 | 0.85 | KMT2A (0.59) | ALDH1A1HTTLMNAHPGDCYP1A2 | |
| SCHEMBL7236077 | 0.84 | ALDH1A1 (0.57) | ALDH1A1HTTLMNAHPGDCYP1A2 | |
| SCHEMBL7236071 | 0.84 | ALDH1A1 (0.57) | ALDH1A1HTTLMNAHPGDCYP1A2 | |
| SCHEMBL548189 | 0.82 | TRIM24 (0.61) | ALDH1A1LMNAHPGDMAPTSMN1; SMN2 | |
| SCHEMBL29955976 | 0.82 | TRIM24 (0.61) | ALDH1A1LMNAHPGDMAPTSMN1; SMN2 | |
| SCHEMBL11716289 | 0.81 | KMT2A (0.62) | ALDH1A1HTTLMNAHPGDCYP1A2 | |
| SCHEMBL7226899 | 0.81 | MAPK1 (0.58) | ALDH1A1HTTLMNAMAPK1MAPT | |
| SCHEMBL699230 | 0.80 | ALDH1A1 (0.71) | ALDH1A1HTTLMNAHPGDCYP1A2 | |
| SCHEMBL2533157 | 0.80 | ALDH1A1 (0.67) | ALDH1A1HTTLMNAHPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6600036-B2 | Treating diseases of the central nervous system. | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-07-29 | — | — | US | disclosed |
| US-20020052364-A1 | Condensed 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-05-02 | — | — | US | disclosed |
| EP-0888356-B1 | CONDENSED 2,3-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS AMPA-RECEPTOR INHIBITORS | SCHERING AG (DE) | 2002-03-20 | — | — | EP | disclosed |
| US-6323197-B1 | NON-COMPETITIVE INHIBITING OF THE AMPA RECEPTORS, THESE COMPOUNDS CAN BE USED AS MEDICAMENTS FOR TREATMENT OF THE CENTRAL NERVOUS SYSTEM | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-27 | — | — | US | disclosed |
| WO-1997040020-A1 | PHTHALAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052364-A1 | Condensed 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors | GABRE, GABRA2, GABRB2 | ALDH1A1 1024/4885HTT 3279/4885LMNA 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.